A randomized trial of intravenous acetaminophen versus indomethacin for treatment of hemodynamically significant PDAs in VLBW infants.
Journal
Journal of perinatology : official journal of the California Perinatal Association
ISSN: 1476-5543
Titre abrégé: J Perinatol
Pays: United States
ID NLM: 8501884
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
received:
06
01
2020
accepted:
11
05
2020
revised:
20
04
2020
pubmed:
23
5
2020
medline:
1
9
2021
entrez:
23
5
2020
Statut:
ppublish
Résumé
Objective was to compare the rate of successful treatment of hsPDA based on echocardiogram criteria after use of IV acetaminophen or IV indomethacin in very low-birthweight infants. The study was a multi-center, randomized controlled trial. Infants born prior to 32 weeks with birthweight ≤ 1500 g were included if PDA treatment was indicated within the 21 days after birth. hsPDA was defined by strict echocardiogram criteria. Eligible infants were randomized to treatment with either IV acetaminophen or IV indomethacin. Of 86 eligible infants, 17 infants were randomized to acetaminophen and 20 to indomethacin. One (5.9%) hsPDA in the acetaminophen group had successful treatment compared to 11 (55%) in the indomethacin group (p = 0.002). Eight (47%) in the acetaminophen group and 3 (15%) in the indomethacin group received transcatheter PDA closure (p = 0.07). IV indomethacin was more effective than IV acetaminophen for treatment of hsPDAs. More infants in the acetaminophen group received transcatheter closure.
Identifiants
pubmed: 32439957
doi: 10.1038/s41372-020-0694-1
pii: 10.1038/s41372-020-0694-1
doi:
Substances chimiques
Acetaminophen
362O9ITL9D
Ibuprofen
WK2XYI10QM
Indomethacin
XXE1CET956
Types de publication
Journal Article
Multicenter Study
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
93-99Références
Alagarsamy S, Chhabra M, Gudavalli M, Nadroo AM, Sutija VG, Yugrakh D. Comparison of clinical criteria with echocardiographic findings in diagnosing PDA in preterm infants. J Perinat Med. 2005;33:161–4.
pubmed: 15843268
Davis P, Turner-Gomes S, Cunningham K, Way C, Roberts R, Schmidt B. Precision and accuracy of clinical and radiological signs in premature infants at risk of patent ductus arteriosus. Arch Pediatr Adolesc Med. 1995;149:1136–41.
pubmed: 7550818
Skelton R, Evans N, Smythe J. A blinded comparison of clinical and echocardiographic evaluation of the preterm infant for patent ductus arteriosus. J Paediatr Child Health. 1994;30:406–11.
pubmed: 7833075
Zonnenberg I, de Waal K. The definition of a haemodynamic significant duct in randomized controlled trials: a systematic literature review. Acta Paediatr. 2012;101:247–51.
pubmed: 21913976
Silverman NH, Lewis AB, Heymann MA, Rudolph AM. Echocardiographic assessment of ductus arteriosus shunt in premature infants. Circulation. 1974;50:821–5.
pubmed: 4418268
Evans N, Iyer P. Longitudinal changes in the diameter of the ductus arteriosus in ventilated preterm infants: correlation with respiratory outcomes. Arch Dis Child Fetal Neonatal Ed. 1995;72:F156–F161.
pubmed: 7796229
pmcid: 2528454
Kluckow M, Evans N. Early echocardiographic prediction of symptomatic patent ductus arteriosus in preterm infants undergoing mechanical ventilation. J Pediatrics. 1995;127:774–9.
Skinner JR, Boys RJ, Hunter S, Hey EN. Non-invasive assessment of pulmonary arterial pressure in healthy neonates. Arch Dis Child. 1991;66:386–90.
pubmed: 2025029
pmcid: 1590313
Su BH, Watanabe T, Shimizu M, Yanagisawa M. Echocardiographic assessment of patent ductus arteriosus shunt flow pattern in premature infants. Arch Dis Child Fetal neonatal Ed. 1997;77:F36–40.
pubmed: 9279181
pmcid: 1720677
Bell EF, Acarregui MJ. Restricted versus liberal water intake for preventing morbidity and mortality in preterm infants. Cochrane Database Syst. Rev. 2014;12:CD000503.
Bell EF, Warburton D, Stonestreet BS, Oh W. Effect of fluid administration on the development of symptomatic patent ductus arteriosus and congestive heart failure in premature infants. N. Engl J Med. 1980;302:598–604.
pubmed: 7351906
Vanhaesebrouck S, Zonnenberg I, Vandervoort P, Bruneel E, Van Hoestenberghe MR, Theyskens C. Conservative treatment for patent ductus arteriosus in the preterm. Arch Dis Child Fetal neonatal Ed. 2007;92:F244–247.
pubmed: 17213270
pmcid: 2675417
Brion LP, Campbell DE. Furosemide for symptomatic patent ductus arteriosus in indomethacin-treated infants. Cochrane Database Syst Rev. 2001;3:Cd001148.
Ohlsson A, Walia R, Shah SS. Ibuprofen for the treatment of patent ductus arteriosus in preterm or low birth weight (or both) infants. Cochrane Database Syst Rev. 2020;2:Cd003481.
pubmed: 32045960
Friedman Z, Whitman V, Maisels MJ, Berman W Jr., Marks KH, Vesell ES. Indomethacin disposition and indomethacin-induced platelet dysfunction in premature infants. J Clin Pharmacol. 1978;18:272–9.
pubmed: 641216
Edwards AD, Wyatt JS, Richardson C, Potter A, Cope M, Delpy DT, et al. Effects of indomethacin on cerebral haemodynamics in very preterm infants. Lancet. 1990;335:1491–5.
pubmed: 1972434
Cifuentes RF, Olley PM, Balfe JW, Radde IC, Soldin SJ. Indomethacin and renal function in premature infants with persistent patent ductus arteriosus. J Pediatr. 1979;95:583–7.
pubmed: 480039
Nagaraj HS, Sandhu AS, Cook LN, Buchino JJ, Groff DB. Gastrointestinal perforation following indomethacin therapy in very low birth weight infants. J Pediatr Surg. 1981;16:1003–7.
pubmed: 7338750
Rheinlaender C, Helfenstein D, Walch E, Berns M, Obladen M, Koehne P. Total serum bilirubin levels during cyclooxygenase inhibitor treatment for patent ductus arteriosus in preterm infants. Acta Paediatr. 2009;98:36–42.
pubmed: 18764861
Waldvogel S, Atkinson A, Wilbeaux M, Nelle M, Berger MR, Gerull R. High dose indomethacin for patent ductus arteriosus closure increases neonatal morbidity [published online ahead of print, 2019 Dec 30]. Am J Perinatol. 2019. https://doi.org/10.1055/s-0039-3400996 .
Coombs RC, Morgan ME, Durbin GM, Booth IW, McNeish AS. Gut blood flow velocities in the newborn: effects of patent ductus arteriosus and parenteral indomethacin. Arch Dis Child. 1990;65:1067–71.
pubmed: 2241229
pmcid: 1590251
Wadhawan R, Oh W, Vohr BR, Saha S, Das A, Bell EF, et al. Spontaneous intestinal perforation in extremely low birth weight infants: association with indometacin therapy and effects on neurodevelopmental outcomes at 18–22 months corrected age. Arch Dis Child Fetal neonatal Ed. 2013;98:F127–132.
pubmed: 22684157
Hammerman C, Bin-Nun A, Markovitch E, Schimmel MS, Kaplan M, Fink D. Ductal closure with paracetamol: a surprising new approach to patent ductus arteriosus treatment. Pediatrics. 2011;128:e1618–e1621.
pubmed: 22065264
Dash SK, Kabra NS, Avasthi BS, Sharma SR, Padhi P, Ahmed J. Enteral paracetamol or intravenous indomethacin for closure of patent ductus arteriosus in preterm neonates: a randomized controlled trial. Indian Pediatrics. 2015;52:573–8.
pubmed: 26244949
El-Mashad AE-R, El-Mahdy H, El Amrousy D, Elgendy M. Comparative study of the efficacy and safety of paracetamol, ibuprofen, and indomethacin in closure of patent ductus arteriosus in preterm neonates. Eur J pediatrics. 2017;176:233–40.
Terrin G, Conte F, Oncel MY, Scipione A, McNamara PJ, Simons S, et al. Paracetamol for the treatment of patent ductus arteriosus in preterm neonates: a systematic review and meta-analysis. Arch Dis Child Fetal Neonatal Ed. 2015;101:F127-36.
Ohlsson A, Shah PS. Paracetamol (acetaminophen) for patent ductus arteriosus in preterm or low birth weight infants. Cochrane Database Syst Rev. 2020;1:Cd010061.
pubmed: 31985831
El Hajjar M, Vaksmann G, Rakza T, Kongolo G, Storme L. Severity of the ductal shunt: a comparison of different markers. Arch Dis Child Fetal neonatal Ed. 2005;90:F419–422.
pubmed: 16113155
pmcid: 1721944
Skinner J. Diagnosis of patent ductus arteriosus. Semin Neonatol. 2001;6:49–61.
pubmed: 11162285
Thomson R. Neofax 2011. New York: Thomson Reuters; 2011.
Bell MJ, Ternberg JL, Feigin RD, Keating JP, Marshall R, Barton L, et al. Neonatal necrotizing enterocolitis. Therapeutic decisions based upon clinical staging. Ann Surg. 1978;187:1.
pubmed: 413500
pmcid: 1396409
Neu J. Necrotizing enterocolitis: the search for a unifying pathogenic theory leading to prevention. Pediatr Clin. 1996;43:409–32.
Papile LA, Burstein J, Burstein R, Koffler H. Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm. J Pediatr. 1978;92:529–34.
pubmed: 305471
Prematurity* CoRo. The international classification of retinopathy of prematurity revisited. Arch Ophthalmol. 2005;123:991–9.
Benitz WE. Patent ductus arteriosus in preterm infants. Pediatrics. 2016;137:e20153730.
Sathanandam S, Whiting S, Cunningham J, Zurakowski D, Apalodimas L, Waller BR, et al. Practice variation in the management of patent ductus arteriosus in extremely low birth weight infants in the United States: survey results among cardiologists and neonatologists. Congenit heart Dis. 2019;14:6–14.
pubmed: 30811803
Liebowitz M, Kaempf J, Erdeve O, Bulbul A, Håkansson S, Lindqvist J, et al. Comparative effectiveness of drugs used to constrict the patent ductus arteriosus: a secondary analysis of the PDA-TOLERATE trial (NCT01958320). J Perinatol. 2019;39:599–607.
Malviya M, Ohlsson A, Shah S. Surgical versus medical treatment with cyclooxygenase inhibitors for symptomatic patent ductus arteriosus in preterm infants. Cochrane Database Syst Rev. 2008;1:Cd003951.
Backes CH, Cheatham SL, Deyo GM, Leopold S, Ball MK, Smith CV, et al. Percutaneous Patent ductus arteriosus (PDA) closure in very preterm infants: feasibility and complications. J Am Heart Assoc. 2016;5:e002923. Published 2016 Feb 12. https://doi.org/10.1161/JAHA.115.002923 .
Sathanandam S, Agrawal H, Chilakala S, Johnson J, Allen K, Knott-Craig C, et al. Can transcatheter PDA closure be performed in neonates </=1000 grams? The Memphis experience. Congenit Heart Dis. 2019;14:79–84.
pubmed: 30811793
Russell JL, Leblanc JG, Potts JE, Sett SS. Is surgical closure of patent ductus arteriosus a safe procedure in premature infants? Int Surg. 1998;83:358–60.
pubmed: 10096762
Weisz DE, More K, McNamara PJ, Shah PS. PDA ligation and health outcomes: a meta-analysis. Pediatrics. 2014;133:e1024–1046.
pubmed: 24639268
Dang D, Wang D, Zhang C, Zhou W, Zhou Q, Wu H. Comparison of oral paracetamol versus ibuprofen in premature infants with patent ductus arteriosus: a randomized controlled trial. PLoS ONE. 2013;8:e77888.
pubmed: 24223740
pmcid: 3817181
Oncel MY, Yurttutan S, Erdeve O, Uras N, Altug N, Oguz SS, et al. Oral paracetamol versus oral ibuprofen in the management of patent ductus arteriosus in preterm infants: a randomized controlled trial. J Pediatr. 2014;164:510–514. e511.
pubmed: 24359938
Palmer G, Atkins M, Anderson B, Smith K, Culnane T, McNally C, et al. IV acetaminophen pharmacokinetics in neonates after multiple doses. Br J Anaesth. 2008;101:523–30.
pubmed: 18628265
Akbari Asbagh P, Zarkesh MR, Nili F, Nayeri FS, Tofighi Naeem A. Prophylactic teatment with oral paracetamol for patent ductus arteriosus in preterm infants: a randomized clinical trial. Tehran Univ Med J TUMS Publ. 2015;73:86–92.
Yang B, Gao X, Ren Y, Wang Y, Zhang Q. Oral paracetamol vs. oral ibuprofen in the treatment of symptomatic patent ductus arteriosus in premature infants: A randomized controlled trial. Exp therapeutic Med. 2016;12:2531–6.
Harkin P, Harma A, Aikio O, Valkama M, Leskinen M, Saarela T, et al. Paracetamol Accelerates closure of the ductus arteriosus after premature birth: a randomized trial. J Pediatr. 2016;177:72–77.e72.
pubmed: 27215779
Al-Lawama M, Alammori I, Abdelghani T, Badran E. Oral paracetamol versus oral ibuprofen for treatment of patent ductus arteriosus. J Int Med Res. 2018;46:811–8.
pubmed: 29239259
Roofthooft DWE, van Beynum IM, de Klerk JCA, van Dijk M, van den Anker JN, Reiss IKM, et al. Limited effects of intravenous paracetamol on patent ductus arteriosus in very low birth weight infants with contraindications for ibuprofen or after ibuprofen failure. Eur J Pediatrics. 2015;174:1433–40.